Selection and Validation of siRNAs Preventing Uptake and Replication of SARS-CoV-2

In 2019, the novel highly infectious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak rapidly led to a global pandemic with more than 346 million confirmed cases worldwide, resulting in 5.5 million associated deaths (January 2022). Entry of all SARS-CoV-2 variants is mediated by...

Full description

Saved in:

Bibliographic Details
Published in:	Frontiers in bioengineering and biotechnology Vol. 10; p. 801870
Main Authors:	Friedrich, Maik, Pfeifer, Gabriele, Binder, Stefanie, Aigner, Achim, Vollmer Barbosa, Philippe, Makert, Gustavo R., Fertey, Jasmin, Ulbert, Sebastian, Bodem, Jochen, König, Eva-Maria, Geiger, Nina, Schambach, Axel, Schilling, Erik, Buschmann, Tilo, Hauschildt, Sunna, Koehl, Ulrike, Sewald, Katherina
Format:	Journal Article
Language:	English
Published:	Switzerland Frontiers Media SA 02.03.2022 Frontiers Media S.A
Subjects:	ACE2 Angiotensin-converting enzyme 2 Bioengineering and Biotechnology Cancer Cells Conserved sequence coronavirus Coronaviruses COVID-19 COVID-19 vaccines Cytoplasmic membranes Disease transmission Drug development Gene silencing Genomes Immunization mRNA Nsp1 Pandemics Penicillin Protein sorting signals Proteins Replication Respiratory tract RNA-mediated interference SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 siRNA Structural proteins therapeutic siRNA Viral infections United States > US COVID-19 ACE2 RNAi SARS-CoV-2 therapeutic siRNA Nsp1 coronavirus
ISSN:	2296-4185, 2296-4185
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!